Patient Support Services Contact Us

Investors

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News
01/14/19
REDWOOD CITY, Calif. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective January 10, 2019 , the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 68,000 shares of the
01/07/19
REDWOOD CITY, Calif. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners .
01/02/19
REDWOOD CITY, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the 37 th annual J.P. Morgan healthcare conference on Tuesday, January 8, 2017 at 7:30 a.m. PT being held in San Francisco .
01/02/19
REDWOOD CITY, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Darlene Horton , M.D. as Chief Medical and Regulatory Affairs Officer. She assumed her role on January 1, 2019 . “We are very pleased that Dr.
Upcoming Events
There are currently no events scheduled.

Receive E-mail Alerts

Click here to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site.

 

Copyright West LLC. Minimum 15 minutes delayed.